More than 350,000 cervical fusion surgeries are reported to be performed each year in the US. It is also said that the procedure volume is growing at nearly twice the rate of lumbar fusion surgeries. California-headquartered medtech Carlsmed aims to accelerate the deployment of patient-centric technology that revolutionises the standard of care for spine surgery.
In a recent development, the AI-enabled personalised surgery medtech company has snapped $52.5 million in a Series C funding round. It was co-led by B Capital and US Venture Partners. These proceeds will be used to accelerate the commercialisation of the aprevo® personalised spine surgery platform for lumbar fusion procedures. Also, the company eyes to launch the aprevo® for cervical fusions in 2025.
Personalised surgery platform
Personalised to your spine and your unique needs, aprevo® uses advanced algorithms and state-of-the-art 3D modeling to develop individualized surgical plans and devices to help you get your power back. It could be the last spine surgery you will ever need.
aprevo® is designed to match every aspect of your spine and gives your surgeon a personalised plan based on your unique situation and the interbody fusion implants to match that plan. Each implant is designed to support your spine in the planned alignment and provide improved load distribution to protect your spine during healing.
AI-enabled personalised surgery
Led by CEO Mike Cordonnier, Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery. It provides a comprehensive digital Solution for surgeons to inform, engage, and empower patients in the pre-operative decision-making process. This helps surgeons and patients achieve aligned expectations for the anticipated benefits of surgery contributing to long-term patient satisfaction.
The Carlsmed implantable devices and software platforms are FDA-cleared for lumbar spine fusion, including anterior, lateral, and transforaminal approaches.
“We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo® patient-specific implants are achieving this goal,” stated Mike Cordonnier, CEO of Carlsmed. “Our AI-enabled technology platform and innovative business model allow us to scale production rapidly to meet growing demand and empower patients.”
Dr. Robert Mittendorff, General Partner and Head of Healthcare at B Capital, said, “Carlsmed is transforming spine surgery through the application of its AI-enabled technology and has proven to be a category creator in a market overdue for meaningful innovation. Personalized surgery will be the standard of care in the spine, and we look forward to supporting this transformation led by Carlsmed.”
